Fudan University
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Private
- Established
- 1905-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.fudan.edu.cn
Pancreatic Cancer With Elevated Serum CA125 Were Compared With Those Who Did Not Receive Neoadjuvant Chemotherapy.
Phase 3
Not yet recruiting
- Conditions
- Pancreatic Adenocarcinoma
- Interventions
- First Posted Date
- 2021-04-08
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 600
- Registration Number
- NCT04835064
c-CetuIRI Versus Ersecond-line Irinotecan s-IRI-CetuIRI
- First Posted Date
- 2021-04-06
- Last Posted Date
- 2021-04-06
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 120
- Registration Number
- NCT04833036
- Locations
- 🇨🇳
Fudan University Cancer Hospital, ShangHai, Shanghai, China
FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver Metastases
Phase 2
Recruiting
- Conditions
- Liver Metastasis Colon Cancer
- Interventions
- First Posted Date
- 2021-04-06
- Last Posted Date
- 2021-04-06
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 160
- Registration Number
- NCT04832776
- Locations
- 🇨🇳
Department of Colorectal Surgery Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Decision-making of ctDNA in Patients With mCRC After Failure of First-line Treatment Containing Cetuximab - a Single-center, Phase II Clinical Study
Not yet recruiting
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2021-04-05
- Last Posted Date
- 2021-04-05
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 100
- Registration Number
- NCT04831528
Gene Abnormalities and Prognosis in Diffuse Large B-cell Lymphoma
- Conditions
- Diffuse Large B Cell Lymphoma, Gene Mutation
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2021-04-01
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 100
- Registration Number
- NCT04825899
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Comparation of Endoscopic Biopsy and Postoperative Specimen for the Molecular Diagnosis of Gastric Cancer
- Conditions
- EndoscopyPathologyStomach NeoplasmsBiopsy
- Interventions
- Procedure: SurgeryDevice: endoscopy
- First Posted Date
- 2021-03-22
- Last Posted Date
- 2021-12-10
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 510
- Registration Number
- NCT04809025
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer
Phase 4
Recruiting
- Conditions
- Invasive Ductal Carcinoma, BreastCarcinoma BreastTriple-negative Breast Cancer
- Interventions
- Drug: Huaier Granule
- First Posted Date
- 2021-03-10
- Last Posted Date
- 2024-06-27
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 1072
- Registration Number
- NCT04790305
- Locations
- 🇨🇳
Union Hospital Tongji Medical College Huazhong Univeristy of Science and Technology, Wuhan, Hubei, China
🇨🇳The Second Affiliated Hospital of Xi'an Jiaotong University (Xibei Hospital), Xi'an, Shanxi, China
🇨🇳The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
mFOLFOXIRI+Bev vs. mFOLFOX6+Bev for RAS Mutant Unresectable Colorectal Liver-limited Metastases
Phase 3
Recruiting
- Conditions
- Colorectal CarcinomaLiver Metastases
- Interventions
- First Posted Date
- 2021-03-04
- Last Posted Date
- 2021-09-27
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 308
- Registration Number
- NCT04781270
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
Adjuvant PD-1 Antibody in Combination With Capecitabine for Patients With ICC at High-Risk of Postoperative Recurrence
Phase 1
- Conditions
- Cholangiocarcinoma, Intrahepatic
- Interventions
- Drug: CapecitabineDrug: PD-1 Antibody（Tislelizumab）
- First Posted Date
- 2021-03-04
- Last Posted Date
- 2022-08-18
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 30
- Registration Number
- NCT04782804
- Locations
- 🇨🇳
Lulu@Huashan.Org.Cn, Shanghai, China
Albumin-bound Paclitaxel Combination With Capecitabine Versus Capecitabine Monotherapy in Paclitaxel/Docetaxel-resistant Advanced Breast Cancer
Phase 2
- Conditions
- Breast Cancer
- Interventions
- Drug: Albumin-bound paclitaxel plus capecitabineDrug: capecitabine
- First Posted Date
- 2021-03-03
- Last Posted Date
- 2021-03-03
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 92
- Registration Number
- NCT04780347
- Locations
- 🇨🇳
Fudan University Shanghai Cancer center, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath